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Objective: Allogeneic hematopoietic stem cell trans-
plantation (Allo-HSCT) is a highly effective post- remission
treatment for patients with AML in ﬁrst complete remission.
The role of post-remission consolidation chemotherapy with
allo-HSCT remains controversial. This study was performed
to evaluate the post-remission chemotherapy efﬁcacy before
Allo-HSCT.
Method: The study included 66 acute leukemia (AML) pa-
tients who received induction regimen containing cytarabine
given for 7 days and idarubicin (7+3) given for 3 days from
April 2008 to July 2013. Thirty -two of patients received only
induction therapy (group A) and 34 patients (group B)
received induction and post-remission chemotherapy con-
taining 5 days cytarabine and 2 days idarubicin (5+2). The
conditioning regimen for transplantation was busulfan and
cyclophosphsmide. Graft-versus-host disease (GvHD) pro-
phylaxis regimen consisted of methotraxate and cyclosporin.
Results: The median follow-up was 20 (21 in group A and
19.5 in group B) months. The median time to neutrophil re-
covery was 12 (range: 9 to 50) and 14 (range: 10 to 27) days
in groups A and B, respectively (p¼0.07). The median time to
platelet recoverywas 15 (9 to 47) days in group A and 16 (9 to
54) days in group B (p¼0.54). Acute GvHD occurred in 18
patients (6 in grade I, 8 in grade II, and 4 in grade III) in group
A and 20 patients (5 grade I, 9 grade II, 6 grade III, and 1 ingrade IV) in group B (56.2% vs. 58.8%; p¼0.833). Eight pa-
tients experienced relapses (7 in group A and 1 in group B).
Twenty-one patients (9 in group A and 12 in group B)
expired. The most common causes of death were GvHD (10),
relapse (5) and infection (4). Two-year leukemia-free sur-
vival (DFS) was 65.9% (SE: 9.5%) and 66.4% (SE: 8.3%) in
groups A and B, respectively (p¼0.547).
Conclusion: The study indicated that there were no differ-
ences in allo-HSCT outcomes between patients with or
without consolidation chemotherapy. More cases and longer
time are required to conﬁrm the preliminary data.216
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Background: Leukemic transformation is seen in approxi-
mately 10-20% of patients with chronic myelomonocytic
leukemia (CMML). We carried out this study to analyze the
clinical features and treatment outcomes in these patients.
Methods: After due IRB approval, 275 patients with WHO
deﬁned CMML seen at the Mayo Clinic from 1997 through
2012 were identiﬁed. All patients underwent bone marrow
(BM) and cytogenetic evaluation at diagnosis and trans-
formation. Patients were evaluated for leukemic trans-
formation and their clinical and pathological information
was retrospectively abstracted.
Results: Of 275 patients with CMML, 42 (15%) had docu-
mented leukemic transformation. The median age at trans-
formation was 68 years (range, 18-87); 21 (50%) were male
and the median follow up was 70 months (range, 37 - 112)
with 34 (79%) deaths recorded at last follow up. At initial
diagnosis 13 patients (31%) had CMML-2. The distribution of
patient across different prognostic models was: Mayo prog-
nostic model- 27 (65%) high risk, 14 (33%) intermediate Risk
and 1 (2%) low risk; Global MD Anderson Score- 11 (26%)
high risk, 11 (26%) intermediate-2 risk, 14 (34%) intermedi-
ate-1 risk and 6 (14%) low risk. Five (12%) patients presented
with elevated white blood counts resulting in leukostasis
(clinical blast crises). Ten of 36 (28%) evaluable patients had
cytogenetic clonal evolution at transformation.
Twenty two (51%) patients with leukemic transformation
received standard induction chemotherapy, 5 (12%) received
hypomethylating agents (HMA) and the remainder were
ineligible for further treatment. Fifteen (68%) patients
treated with induction chemotherapy achieved a ﬁrst com-
plete remission (CR1) in comparison to only one (20%) with a
HMA. The median survival after transformation for patients
achieving CR1 was 28 vs. 2.4 months for the rest of the group
(Fig 1, p<0.001). Seven (32%) patients who underwent in-
duction chemotherapy eventually proceeded with allogeneic
stem cell transplantation (SCT) (4 matched unrelated donor,
2 matched related donor and 1 Cord blood transplant), of
which one (14%) relapsed shortly after SCT; the remainder
are currently alive and disease free. Among patients
achieving a CR1, the median survival for patients undergoing
allogeneic SCT was not reached compared to 25 months for
the remainder (Fig 2, p<0.001).
In a univariable analysis, receiving induction chemo-
therapy (p¼0.016), achieving a CR1 (p<0.001) andundergoing
Fig 1.
Fig 2.
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tors predicting improved survival; however in a multivariable
model, achieving a CR1 (p¼0.002) and undergoing allogeneic
SCT retained prognostic signiﬁcance (p¼0.01).
Conclusion: Leukemic transformation from CMML is asso-
ciated with poor outcomes. For eligible patients, induction
chemotherapy followed by allogeneic SCT seems to offer the
best chances for achieving durable remissions.217
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complete remission (CR1) has become a standard of care for
many patients (pts) with intermediate or high risk acute
myeloid leukemia (AML). Furthermore, pts with relapsed
AML may be salvaged by re-induction and subsequent
alloSCT. Here, we analyzed the outcome of pts with AML
transplanted beyond CR1 at our center between 1996 and
2013.
Pts and Methods: 120 pts (50 female, 70 male) with a me-
dian age of 49 (19-72) years were retrospectively analyzed as
of June 30th, 2013. 92 pts had de novo AML and 28 pts had
secondary or therapy-related AML. 63 pts were in CR2
whereas 57 pts were refractory to re-induction therapy and
had active disease at the time of alloSCT. The SWOG/ECOG
cytogenetic risk proﬁle was favorable in 16 pts, intermediate
in 53 pts, and unfavorable in 34 pts (unknown: 11 pts, un-
determined: 6 pts). Conditioning consisted of a 12 Gy TBI-
basedmyeloablative regimen (MAC) in 51 pts. 61 pts received
reduced intensity conditioning (RIC: FLU/BU/ATG) and 9 pts
were conditioned using the FlamsaRIC protocol. A matched
related donor was available in 33 pts. 62 pts had a matched-
unrelated donor and 25 pts had a mismatched unrelated
donor.
Results: After a median follow-up of 39 (3-185) months, 44
pts are alive and in CR. Causes of death were relapse in 37 pts
or non-relapse mortality (NRM) in 36 pts. At 1, 3, and 5 years
after alloSCT projected overall survival (OS) or disease-free
survival (DFS) of the entire cohort was 50% (41-60%), 40%
(30-50%), and 39% (29-49%) or 48% (39-58%), 39% (30-49%),
or 38% (28-47%). At the same time points the cumulative
incidence of relapse (CIR) or NRM (CINRM)was 25% (19-35%),
31% (23-41%), and 32% (24-42%) or 25% (21-38%), 28% (21-
38%), or 30% (22-40%). In univariate analysis pts refractory to
re-induction therapy had a signiﬁcantly lower 3-year DFS
(26%) as compared to pts transplanted in CR2 (54%) (HR 1.8
(95%CI: 1.1-2.8), p¼0.01), due to an increased relapse rate
(40% vs 24%, p¼0.003). Similarly, an interval of 12 months
from diagnosis to alloSCT was predictive for a lower 3-year
DFS as compared to an interval of >12 months (21% vs 52%)
(HR 2.0 (95%CI: 1.2-3.3), p¼0.002), due to an increased
relapse incidence (47% vs 23%, p<0.001). All other factors
examined, i.e. gender, cytogenetic risk, AML subtype, age
group, type of conditioning, donor, or year of alloSCT, were
not predictive for OS, DFS, CIR, or CINRM. In multivariate
analysis, remission status and time from diagnosis to trans-
plantation were identiﬁed as independent prognosticators
for OS, DFS, and CIR.
Conclusions: In sum, our data indicate that pts with AML
beyond CR1 may be successfully salvaged by alloSCT. In
particular, pts transplanted in CR2 beneﬁt the most. Pts re-
fractory to re-induction may be candidates for alloSCT as
well. However, these pts have a poorer outcome due to a high
relapse rate irrespective of the cytogenetic risk proﬁle and
the conditioning regimen used.218
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Introduction: Patients with acute myeloid leukemia (AML)
refractory to induction chemotherapy have dismal progno-
ses. Although allogeneic stem cell transplant (allo-SCT)
